MHC Class I Antigens In Malignant Cells : Immune Escape And Response To Immunotherapy
Aptsiauri, Natalia
MHC Class I Antigens In Malignant Cells : Immune Escape And Response To Immunotherapy by Natalia Aptsiauri, Angel Miguel Garcia-Lora, Teresa Cabrera - New York Springer International Publishing 2013 - 1 recurso en línea (VIII, 51 p.) 17 il., 14 il. col. - SpringerBriefs in Cancer Research 6 . - SpringerBriefs in Cancer Research 6 .
Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrenceÂt ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches.Âcomplete characterization of these molecular defects is important for improvement of the strategies for the selection and follow-up of patients undergoing T-cell based cancer immunotherapy. Âcise identification of the mechanism leading to MHC class I defects Âl help to develop new personalized patient-tailored treatment protocols.Âre is significant new researchÂthe prevalence of various patterns of MHC class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data isÂilable on the changes in MHC class I expression during the course of cancer immunotherapy, but the authors have recently made discoveries thatÂwÂÂgression or regression of a tumor lesion in cancer patients undergoing immunotherapy depends on the molecular mechanism responsible for the MHC class I alteration and not on the type of immunotherapy used. According to this notion, the nature of the preexisting MHC class I lesion in the cancer cell has a crucial impact onÂermining the final outcome of cancer immunotherapy.Âs SpringerBrief will present MHC class 1 is expressed, explain its role in tumor progression, and its role in resistance to immunotherapy. Â
9781461465430
Cáncer--Aspectos inmunológicos
RC268.3 / A687 2013 EB
MHC Class I Antigens In Malignant Cells : Immune Escape And Response To Immunotherapy by Natalia Aptsiauri, Angel Miguel Garcia-Lora, Teresa Cabrera - New York Springer International Publishing 2013 - 1 recurso en línea (VIII, 51 p.) 17 il., 14 il. col. - SpringerBriefs in Cancer Research 6 . - SpringerBriefs in Cancer Research 6 .
Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrenceÂt ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches.Âcomplete characterization of these molecular defects is important for improvement of the strategies for the selection and follow-up of patients undergoing T-cell based cancer immunotherapy. Âcise identification of the mechanism leading to MHC class I defects Âl help to develop new personalized patient-tailored treatment protocols.Âre is significant new researchÂthe prevalence of various patterns of MHC class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data isÂilable on the changes in MHC class I expression during the course of cancer immunotherapy, but the authors have recently made discoveries thatÂwÂÂgression or regression of a tumor lesion in cancer patients undergoing immunotherapy depends on the molecular mechanism responsible for the MHC class I alteration and not on the type of immunotherapy used. According to this notion, the nature of the preexisting MHC class I lesion in the cancer cell has a crucial impact onÂermining the final outcome of cancer immunotherapy.Âs SpringerBrief will present MHC class 1 is expressed, explain its role in tumor progression, and its role in resistance to immunotherapy. Â
9781461465430
Cáncer--Aspectos inmunológicos
RC268.3 / A687 2013 EB